Importance of low-grade albuminuria

被引:71
作者
Danziger, John [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA USA
关键词
D O I
10.4065/83.7.806
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The well-described association between chronic kidney disease and cardiovascular disease is typically thought to originate from loss of renal function, as estimated by the glomerular filtration rate. However, recent data suggest that urinary albumin excretion has an important role in this association. Albuminuria is a marker of underlying vascular dysfunction and has been correlated with structural and functional integrity of the vasculature. Although the traditional upper limit of normal daily albumin excretion has been 30 mg/d, recent epidemiologic data suggest that levels in the general population are actually much lower. Further, within this range of low-grade albuminuria (LGA), increasing excretion rates are associated with increasing risk of cardiovascular disease. This association is independent of renal function, and in the earliest stages of chronic kidney disease, LGA seems to be a more important determinant than the glomerular filtration rate. This emerging association underscores the complexity of albumin excretion, in which subtle changes in albumin excretion reflect widespread vascular processes. Using the key words albuminuria, low-grade albuminuria, and microalbuminuria in a PubMed search of literature from January 1, 1995, to February 29, 2008, this review summarizes the most recent data on LGA and its association with cardiovascular and renal disease.
引用
收藏
页码:806 / 812
页数:7
相关论文
共 94 条
[1]   Antiproteinuric effect of oral paricalcitol in chronic kidney disease [J].
Agarwal, R ;
Acharya, M ;
Tian, J ;
Hippensteel, RL ;
Melnick, JZ ;
Qiu, P ;
Williams, L ;
Batlle, D .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2823-2828
[2]  
[Anonymous], 2006, USRDS 2006 ANN DAT R
[3]   Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals -: The Framingham heart study [J].
Ärnlöv, J ;
Evans, JC ;
Meigs, JB ;
Wang, TJ ;
Fox, CS ;
Levy, D ;
Benjamin, EJ ;
D'Agostino, RB ;
Vasan, RS .
CIRCULATION, 2005, 112 (07) :969-975
[4]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[5]   Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures [J].
Axel, DI ;
Riessen, R ;
Runge, H ;
Viebahn, R ;
Karsch, KR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (04) :619-629
[6]   Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk? [J].
Bakker, SJL ;
Gansevoort, RT ;
Stuveling, EM ;
Gans, ROB ;
de Zeeuw, D .
CURRENT HYPERTENSION REPORTS, 2005, 7 (05) :379-384
[7]   The relationship between flow-mediated olatation and left ventricular function in type 2 diabetic patients with microalbuminuria [J].
Baykan, Merih ;
Erdogan, Turan ;
Erem, Changir ;
Hacihasanoglu, Arif ;
Gedikli, Omer ;
Kucukosmanoglu, Mehmet ;
Celik, Sukru ;
Orem, Cihan .
ENDOCRINE, 2006, 30 (02) :197-202
[8]   Microalbuminuria during acute myocardial infarction - A strong predictor for 1-year mortality [J].
Berton, G ;
Cordiano, R ;
Palmieri, R ;
Cucchini, F ;
De Toni, R ;
Palatini, P .
EUROPEAN HEART JOURNAL, 2001, 22 (16) :1466-1475
[9]   Association between hyperlipidemia and microalbuminuria in essential hypertension [J].
Campese, VM ;
Bianchi, S ;
Bigazzi, R .
KIDNEY INTERNATIONAL, 1999, 56 :S10-S13
[10]   Inducible myocardial ischaemia in asymptomatic Type 2 diabetic patients [J].
Castells, I ;
Salinas, I ;
Rius, F ;
Fraile, M ;
Rubio, L ;
Pereferrer, D ;
Romero, R ;
Sanmartí, A .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2000, 49 (2-3) :127-133